<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1496">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087396</url>
  </required_header>
  <id_info>
    <org_study_id>KC.CR.I.AM.16.2</org_study_id>
    <nct_id>NCT03087396</nct_id>
  </id_info>
  <brief_title>A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Foot/Ankle</brief_title>
  <official_title>A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Foot/Ankle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post Market clinical outcomes study to collect data on the short - and long-term outcomes
      for subjects who are undergoing or who have undergone the Subchondroplasty Procedure in the
      foot and/or ankle in a standard clinical setting. Outcomes to be assessed include pain
      medication usage, pain, function, activity levels and patient satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post-market, multi-center, patient outcomes centered study to evaluate the
      on-label use of AccuFill during the Subchondroplasty procedure (SCP). Enrolled subjects will
      sign an informed consent form, satisfy the inclusion/exclusion criteria and have at least
      one bone marrow lesion, such as a cyst or stress fracture confirmed by diagnostic imaging in
      the foot and/or ankle joint. Demographics, medical history and medications will recorded at
      the time of enrollment. Surgical details including the SCP procedure, concomitant surgical
      procedures and intraoperative safety events will be recorded. Subjects will complete
      validated patient reported outcomes measures pre-operatively including the Foot Function
      Index (FFI) revised short form, the EQ-5D™ and numeric pain score. These measures plus a
      subject satisfaction survey will also be administered post-operatively at 6 weeks, 3 months,
      6 months, 1 year, 2 years. At 3 years, 4 years, and 5 years, numeric pain scores and a
      patient satisfaction survey will be collected. Screening for adverse events and revision
      surgeries will occur throughout the study.

      Target enrollment is 250 patients at up to 25 clinical sites. Subjects will complete the
      study at 5 years or will be withdrawn if the patient undergoes revision surgery of the
      Subchondroplasty site.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2017</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Foot Function Index-Revised (FFI-R) short form score at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline score, range 0-100, for patient reported pain, stiffness, difficulty, activity limitation and social issues at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of device and/or procedure related adverse events and re-visions/re-operations</measure>
    <time_frame>5 years</time_frame>
    <description>Summary and description of procedure and device related adverse events and surgical re-operations and relatedness to the bone substitute material and procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in numeric pain score from baseline at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in numeric pain score using a 0-10 scale from baseline at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol-5 Dimensions (EQ-5D) from baseline at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in patient quality of life from baseline at 12 months. A scoring function is created using a population preference weighted health index. The change from the baseline score will be measured at 12 months.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Insufficiency Fractures</condition>
  <condition>Microfracture</condition>
  <condition>Stress Fracture</condition>
  <condition>Stress Fracture, Ankle, Foot and Toes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment of insufficiency fractures</intervention_name>
    <description>Filling of micro fractures or insufficiency fractures with a bone substitute material</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 250 subjects, each with at least one bone marrow lesion (BML) in any of the
        bones of the foot and/or ankle who have elected to undergo or have undergone the
        Subchondroplasty (SCP) procedure will be enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has at least one bone defect such as a bone marrow lesion (BML), cyst or
             stress fracture confirmed by diagnostic imaging

          -  Surgeon considers the patient appropriate for the SCP procedure

          -  Subject provides voluntary signature on the Institutional Review Board (IRB) approved
             Informed Consent

          -  Subject is at least 18 years of age

          -  Subject must be physically and mentally willing and able, in the Investigator's
             opinion at the time of enrollment, to complete outcome forms via the internet,
             telephone or regular mail

        Exclusion Criteria:

          -  Subject is pregnant at the time of surgery

          -  Subject is incarcerated

          -  Subject is involved in active litigation related to the condition being treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OrthoCarolina Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne D Rahme, BA</last_name>
    <phone>484-873-3343</phone>
    <email>marianne.rahme@zimmerbiomet.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynsey Boyle, BS</last_name>
    <phone>484-467-7047</phone>
    <email>lynsey.boyle@zimmerbiomet.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OrthoNorcal</name>
      <address>
        <city>Capitola</city>
        <state>California</state>
        <zip>95010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clay Christensen, BS</last_name>
      <phone>831-475-4024</phone>
      <email>cchristensen@orthonorcal.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Abidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Orthopaedics &amp; Sports Medicine</name>
      <address>
        <city>Exton</city>
        <state>Pennsylvania</state>
        <zip>19341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Hollinger, DPM</last_name>
      <phone>610-280-1578</phone>
      <email>jhollinger@premierortho.com</email>
    </contact>
    <investigator>
      <last_name>Jason R Miller, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>February 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone marrow defect</keyword>
  <keyword>bone marrow lesion</keyword>
  <keyword>stress fracture</keyword>
  <keyword>calcium phosphate</keyword>
  <keyword>bone substitute material</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Fractures, Stress</mesh_term>
    <mesh_term>Ankle Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
